As of December 31, 2010 the Life Raft Group’s Patient Registry has now accounted for 1,279 cases of GIST. The members of this registry have reported their clinical information to us as it pertains to their treatment of GIST. Of these 1,279 cases, we are here to report some key demographics that will help you understand who is a part of Life Raft Group GIST Community.
“I learned a lot and feel so much better having the NIH team as an additional resource, “said LRG member, Anne Pacifico.
At the American Society of Clinical Oncology Gastrointestinal (GI ASCO) Symposium January 20, 2011, researchers reported progression-free and overall survival benefit in newly diagnosed advanced GIST patients in an ongoing Masitinib (AB1010) Phase II trial in France.
Bayer initiates a randomized Phase III trial of Regorafenib in GIST: On January 10, 2011 Bayer Healthcare in Berlin, Germany announced the initiation of a randomized phase III trial of Regorafenib (BAY 73-4506) for Gastrointestinal Stromal Tumor patients.
Yesterday, there were a series of news stories reporting on an article published by Cooke et al inCancer Cell. Unfortunately, the coverage gave misleading information which could suggest that patients should not take Gleevec (imatinib) or Sutent (sunitinib).
Here is David J Brandis' in memoriam page. His legacy lives on to this day with his family and friends at Prairie Dental Group in IL.
This video is a look at where the LRG has been and where it is going.
Here is a video of Dr. George Demetri speaking about GIST in 2010.
A beautiful spirit & consummate caregiver, Rita Catherine Joyce Patient touched the lives of all she knew. Proud wife, mother & grandmother, she passionately supported her family in all of their endeavors. She enjoyed & treasured the blessings of many lifelong friends in Minnesota & Texas & her travels to points beyond.
Matthew Allen Arluck, of Chicago, passed away at his parents’ home surrounded by his immediate family on Thursday, Nov. 26, 2009. He was 39 years old.
